Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBC1 domain family member 7 (TBC1D7) is a protein that serves as the third core subunit of the tuberous sclerosis complex (TSC), binding to TSC1 and stabilizing the TSC1-TSC2 complex, which is a major negative regulator of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway controlling cell growth, autophagy, and differentiation. Unlike other TBC-domain proteins, TBC1D7 lacks critical Rab-GAP catalytic motifs and thus is not a classical GTPase-activating protein, though weak activity toward Rab17 has been described in vitro. Pathologically, biallelic mutations in TBC1D7 are associated with neurodevelopmental disorders including intellectual disability and megalencephaly, while increased expression has been linked to susceptibility in certain cancers and migraine. TBC1D7 is not a therapeutic target in the classical sense (e.g., receptor, enzyme, transporter) and no approved or experimental drugs are known to directly target it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBC1 domain family member 7 (TBC1D7).